Life Sciences Intellectual Property Lawyers | McDermott

Life Sciences
Intellectual Property


IAM Patent 1000

As a life sciences company, your intellectual property (IP) is your most valuable asset—it’s what propels your growth, drives your success and sets you apart from competitors. But it may also be your most vulnerable asset.

How you commercialize your innovation and gain compliance is crucial for the success of your business. As competitors constantly work to capture your share of the market, it is imperative that your IP is protected to maximize its value. Our business-first perspective makes us uniquely equipped to help our clients build formidable IP portfolios, maximize their value and enforce or defend them in litigation.

Show More


  • Representing United Therapeutics in its patent infringement suit against Liquidia Technologies alleging Liquidia infringes patents related to UT’s Tyvaso (treprostinil) product, a prescription inhalation solution for pulmonary arterial hypertension.
  • Representing Astellas in multiple patent infringement cases regarding its Lexiscan® product, a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress, as well as cases involving Myrbetriq® and XOSPATA®.
  • Successfully represented Amgen in defeating efforts by Sanofi’s and Regeneron to declare Amgen’s patents, covering a new class of cholesterol lowering anti-PCSK9 antibodies, invalid in this closely watched competitor case; secured a sweeping jury verdict after a one-week jury trial.

Show More


We provide a full array of legal services to help you take your IP further.